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Anti‑biofilm efficacy of a medieval 
treatment for bacterial infection 
requires the combination 
of multiple ingredients
Jessica Furner‑Pardoe1,2,9*, Blessing O. Anonye1,7,9, Ricky Cain1,8, John Moat3, 
Catherine A. Ortori4, Christina Lee5, David A. Barrett4, Christophe Corre1,6 & Freya Harrison1*
Novel antimicrobials are urgently needed to combat drug‑resistant bacteria and to overcome the 
inherent difficulties in treating biofilm‑associated infections. Studying plants and other natural 
materials used in historical infection remedies may enable further discoveries to help fill the antibiotic 
discovery gap. We previously reconstructed a 1,000‑year‑old remedy containing onion, garlic, wine, 
and bile salts, known as ‘Bald’s eyesalve’, and showed it had promising antibacterial activity. In this 
current paper, we have found this bactericidal activity extends to a range of Gram‑negative and Gram‑
positive wound pathogens in planktonic culture and, crucially, that this activity is maintained against 
Acinetobacter baumannii, Stenotrophomonas maltophilia, Staphylococcus aureus, Staphylococcus 
epidermidis and Streptococcus pyogenes in a soft‑tissue wound biofilm model. While the presence of 
garlic in the mixture can explain the activity against planktonic cultures, garlic has no activity against 
biofilms. We have found the potent anti‑biofilm activity of Bald’s eyesalve cannot be attributed to 
a single ingredient and requires the combination of all ingredients to achieve full activity. Our work 
highlights the need to explore not only single compounds but also mixtures of natural products 
for treating biofilm infections and underlines the importance of working with biofilm models when 
exploring natural products for the anti‑biofilm pipeline.
Widespread multidrug resistance of once-susceptible pathogens, combined with a lack of success in developing 
novel antimicrobials, has resulted in a looming crisis. Antimicrobial resistance leads to problematic infections, 
threatens the success of routine surgery and cancer  treatments1, and is estimated to kill 10 million people per year 
by  20502,3. One particularly troublesome area is biofilm-associated infection. Biofilm infections are estimated 
to cost the UK’s National Health Service over a billion pounds every year, with this cost only set to  increase4,5. 
Biofilms are communities of bacteria that produce a protective extracellular matrix and are especially  persistent6. 
Biofilm eradication often requires 100–1,000 times higher antibiotic concentrations to achieve clearance than 
the same bacteria growing planktonically (as individual free-floating cells)7. In vivo, biofilms may essentially be 
completely impervious to antibiotic  treatment8.
The path to overcoming biofilm infections requires a multifaceted response, including the discovery and clini-
cal deployment of novel antimicrobials. This search for novel candidates must be directed towards those patho-
genic bacteria with the highest health and economic impact (e.g. ESKAPE  group9,10) and will be expedited if early 
discovery work on leads takes into account the inherent difficulties of treating biofilm-associated  infections6,11.
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The heightened urgency for novel antibiotics has resulted in natural products being revisited. Just 200 years 
ago, our pharmacopoeia was dominated by herbal medicines. These medicines have had varying levels of suc-
cess for the treatment of infections in modern research, with a number of potent compounds against planktonic 
cultures being  identified12,13; however, these have been far less successful against biofilm cultures. We do not 
fully understand the reasons for this lack of translational success of plant extracts.
It could be that the conventional process for developing drugs may miss key aspects of those herbal remedies 
which could be effective against biofilms. Conventional drug development calls for the isolation of single active 
compounds, whereas historical medicine usually calls for combinations of whole plants (and other natural materi-
als). There is some evidence that whole plant extracts can have stronger biological effects than individual isolated 
 compounds14. Examples of such synergy include observations that the anti-malarial activity of artemisinin is 
enhanced by the presence of other compounds from the same  plant15,16 or the combination of flavonoids used 
in  Citrox14. Synergy may result from the presence of molecules which potentiate the activity of antimicrobial 
compounds, or from multiple active compounds with different mechanisms of action. It is also possible that in 
purifying individual compounds to achieve readily quantifiable and characterised treatments, we may lose vital 
interactions of natural products within the original mixture which prevent irritation or toxicity.
Additionally, research into natural antimicrobial products is often limited by a methodological focus on 
planktonic activity testing. The current gold standard for antibacterial testing is broth microdilution, usually 
conducted in cation-adjusted Mueller–Hinton  Broth17, and this is used extensively for the discovery of novel 
antibacterial compounds. However, whilst providing a great high-throughput screening method, this does not 
provide information on how the test substance interacts with bacteria in biofilms, or in settings which better 
mimic the chemical environment experienced by pathogens in vivo17,18. This focus may in part explain the lack 
of translational success of isolated plant compounds, as their activity may be sufficient to kill planktonic cells, 
but not to penetrate or kill biofilms—i.e. by not using biofilm assays, we create a high false positive rate in the 
early stages of activity testing.
In this paper, we investigate the importance of the combination of ingredients for the anti-biofilm activity of 
a tenth century remedy used for eye infection from the manuscript known as Bald’s Leechbook (London, British 
Library, Royal 12, D xvii). This remedy has previously been shown to kill S. aureus biofilms by Harrison et al. 
(2015)19, Pseudomonas aeruginosa planktonic  cultures20 and recently Neisseria gonorrhoeae in a disk diffusion 
 assay21. The recipe, known as ‘Bald’s eyesalve’, requires equal volumes of garlic (Allium sativum) and another 
Allium species (referred to as cropleac in the original Old English) to be crushed together and mixed with equal 
volumes of wine and ox gall (bovine bile). We now report two key new findings. First, we show the bactericidal 
activity of Bald’s eyesalve against a panel of clinically relevant strains of ESKAPE pathogens in planktonic culture, 
and against biofilms of a subset of these strains. Second, we conducted a detailed assessment of whether (a) any 
individual ingredient or (b) the sulphur-containing compound allicin (from garlic) can explain this activity. No 
single ingredient recaptures the anti-biofilm activity of Bald’s eyesalve, and the presence of allicin cannot fully 
explain the ability of the whole mixture to kill either planktonic cultures grown in host-mimicking medium 
(synthetic wound fluid), or biofilms grown in an in vivo-like model of a soft tissue wound. The combination of 
ingredients in the full mixture is the key to the remedy’s apparent efficacy, and this is only apparent when it is 
tested in host-mimicking models as opposed to planktonic cultures in standard laboratory medium.
Results
Consistent anti‑biofilm activity of Bald’s eyesalve and decision to use onion (Allium cepa) 
as “cropleac”. The meaning of Old English cropleac, as used in the original remedy, is ambiguous and may 
refer to a variety of Allium  species22,23. Two likely translations are onion (Allium cepa) or leek (Allium porrum). 
For this reason, multiple batches of the remedy using either Allium species were made in our laboratory between 
2014 and 2019. After the 9-day brewing period, the activity of the remedies was tested against mature biofilms 
of S. aureus Newman in an in vivo-like model of a soft tissue wound. In this assay, 24-h-old biofilms, that have 
been grown at 37 °C in collagen-based synthetic wounds, are exposed to Bald’s eyesalve or water for 24 h, and 
surviving bacteria are  counted19,24.
In total, 75 batches of Bald’s eyesalve were made, including 15 pairs of batches where onion (ESO) and leek 
(ESL) variants were made at the same time, using the same garlic, wine and bile. As shown in Fig. 1A, biofilm 
killing was achieved by 14/15 paired batches, with 22/30 preparations causing a > 3-log drop in viable bacteria, 
when compared with water-treated control biofilms. The mean log drop was not significantly different between 
paired ESO and ESL batches (paired t-test  t14 = 0.025, p = 0.981). We tested one example pair of ESO and ESL 
variants (batch 6) against a panel of twelve clinical isolates of S. aureus grown in the synthetic wound biofilm 
model. As shown in Fig. 1B, ESO consistently showed more bactericidal activity than ESL. This result may be due 
to the presence of antimicrobial compounds unique to onion, or it may simply be due to onions being easier to 
crush in a mortar and pestle, potentially making the extraction of natural compounds more efficient. To simplify 
further analysis, follow on work was focussed on ESO.
As shown in Fig. 2, biofilm killing was consistently achieved by multiple batches of ESO. Of these batches, 
62 of the 75 caused a > 3-log drop in viable CFU, with 45/75 causing > 5 log drop, and 28 of these causing > 6-log 
drop, all relative to control biofilms treated with sterile water.
Broad‑spectrum antibacterial activity of Bald’s eyesalve against common wound patho-
gens. The antibacterial activity of three batches of ESO was tested in both planktonic and biofilm cultures 
of eight strains of bacteria that commonly cause chronic wound infections. As shown in Fig. 3, ESO had potent 
activity against planktonic cultures of Gram-negative (P. aeruginosa PA14, A. baumannii clinical isolate, E. cloa-
cae, S. maltophilia) and Gram-positive (S. aureus Newman, S. aureus USA300, S. epidermidis and S. pyogenes) 
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wound pathogens. ESO eradicated all planktonic cultures in all strains tested with the exception of S. aureus 
USA300 and S. maltophilia, where a 3–4 log drop in viable bacteria was seen.
Mature biofilms of the above isolates were grown in the synthetic wound model and treated with the same 
batches of eyesalve used for planktonic killing experiments. A 2–6-log drop in viable cells was observed for 
the Gram-positives S. aureus Newman, S. aureus USA300, S. epidermidis, S. pyogenes and the Gram-negative 
A. baumannii (Fig. 4). No or inconsistent killing was observed for P. aeruginosa, E. cloacae and S. maltophilia 
biofilms (Fig. S3).
Figure 1.  The activity of Bald’s eyesalve, ESO and ESL variants, against S. aureus. (A) 15 pairs of Bald’s eyesalve 
translating cropleac as either onion (ESO, grey) and leek (ESL, white), were prepared at the same time (batches 
1–15). Their activity was assessed against S. aureus Newman biofilms. Mature biofilms of S. aureus Newman 
were grown in a model of a soft tissue wound, then treated with either sterile water or Bald’s eyesalve (n = 3–5 
replicates per treatment) for 24 h before recovering bacteria for CFU counts. The mean log change in viable 
bacteria in treated vs control wounds was calculated for each preparation and no significant difference was seen 
(paired t-test  t14 = 0.025, p = 0.981). Raw data are supplied in the Data Supplement. (B) Six carriage isolates of S. 
aureus, and six isolates from a chronic post-surgical wound (detailed in Table 4), were grown in the synthetic 
wound biofilm model and treated with ESO, ESL or water (n = 3 per treatment). Each strain grew to different 
densities in untreated wounds (range approx.  106–108). The  log10 drop in bacteria associated with treatment was 
calculated for each treated wound relative to the mean CFU in the three untreated wounds. Log drop data was 
analysed by ANOVA which revealed significant differences in log drop between eyesalve variants  (F1,48 = 732, 
p < 0.001) and strains  (F11,48 = 14.4, p < 0.001) and a significant strain-dependent difference in the magnitude of 
the effect of eyesalve variant (strain*variant interaction  F11,48 = 8.66, p < 0.001). The family-wise error rate was 
calculated from the ANOVA table and used to conduct planned contrasts of ESO vs ESL treatment effects for 
each strain using t-tests. ESO caused a larger reduction in viable cells than ESL for all strains (all p < 0.001). Raw 
data and R scripts are supplied in the Data Supplement.
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Garlic is responsible for the majority of planktonic killing by ESO. Our initial work indicated that 
all four ingredients in ESO were required to kill biofilms of S. aureus Newman in synthetic wound  biofilms19. A 
recent publication by Fuchs et al. (2018;20) concluded that the bactericidal activity of ESO was due to the pres-
ence of allicin from garlic, however, the Fuchs et al. study only investigated planktonic killing in standard Muel-
ler–Hinton Broth (MHB). It is well known that planktonic cultures of bacteria can be up to 1,000 times more 
sensitive to antibiotics than the same isolates grown as  biofilms7, and that antibiotic sensitivity is highly depend-
ent on growth  medium25. This means conducting assays only on planktonic MHB cultures risks underestimating 
the number or concentration of bioactive agents in ESO required for killing in in vivo-like  conditions17,18.
To more robustly determine if the activity of ESO stems from one ingredient or several, we prepared indi-
vidual ingredients and preparations omitting one ingredient, such that the concentrations of each ingredient in 
the whole remedy and the single ingredient or dropout variants were equal. The MICs of these preparations, along 
with MICs of the full recipe, were assessed in MHB and in SWF, in standard broth microdilution assays using 
four of the isolates previously tested (two Gram-negatives, A. baumannii clinical isolate strain and P. aeruginosa 
PA14, and two Gram-positives, S. aureus Newman and S. aureus USA300).
As shown in Table 1, the bacterial isolates varied in their sensitivity to the full ESO. Crucially, there was an 
effect of the growth medium, such that MICs at least doubled in SWF compared with MHB for S. aureus New-
man and A. baumannii. Wine, bile or onion alone were much less effective than the full remedy. In MHB, the 
MIC of garlic alone was the same as the ESO MIC for all strains except P. aeruginosa, and in SWF the garlic and 
ESO MICs were either equal or exhibited a max. twofold difference. This suggests that the planktonic activity 
of the remedy is due to the presence of garlic. The results of MIC testing with ingredients omitted gave similar 
results (Table 2). Preparations omitting garlic lost all or most of their antibacterial activity. Removal of any 
other ingredient left activity largely unaffected, although the omission of wine or bile doubled the MIC against 
P. aeruginosa PA14 in SWF. The discordance between MICs in different media is more prominent here, with the 
removal of an ingredient having a minimal effect in MHB but a large loss in activity when tested in SWF. This 
stresses the common discordance between testing in standard rich lab medium and host-mimicking medium.
All four ingredients are necessary for activity against mature S. aureus biofilms in synthetic 
wounds. Consistent with previous results from our group, no single ingredient alone had any bactericidal 
activity against mature S. aureus Newman biofilms in the synthetic wound model, and removing any single 
ingredient resulted in a reduction in the anti-biofilm activity (Fig. 5). Surprisingly, removal of wine caused a 
decrease in activity on par with that seen with the removal of garlic, despite wine possessing very limited anti-
microbial activity on its own in either biofilm or planktonic assays (Table 1). For comparison with planktonic 
MIC data, the final concentration of Bald’s eyesalve in synthetic wound biofilm killing assays (Figs. 1, 2, 3, 4, 5, 
6), is 33% vol/vol. Therefore, in more in vivo-like biofilm conditions, combining all the ingredients is necessary 
for full activity against S. aureus Newman.
The antibacterial activity of ESO is not simply due to its allicin content. The study which attrib-
uted the planktonic activity of ESO to garlic further concluded that this was specifically due to the presence 
of  allicin20, an organosulfur compound with well known, potent antimicrobial activity in vitro26–28. We used 
HPLC, calibrated against allicin standards of known concentrations, to determine the allicin concentration in 
12 batches of fresh ESO. These batches were then assayed for MIC against S. aureus Newman in SWF. We were 
then able to calculate the concentration of allicin present in the MIC of each batch and compare this with the 
MIC of purified allicin.
As shown in Table 3, the allicin concentration in the 12 batches of ESO was found to be in the range of 
391 ± 19 μg·ml−1. Therefore, the estimated concentration of allicin in their respective MICs would be in the range 
11—39 μg·ml−1. This is much lower than the MIC obtained for purified allicin, which was 62.5 μg·ml−1. Due to 
Figure 2.  The activity of 75 Bald’s eyesalve (ESO) batches made by our group against S. aureus Newman 
biofilms. Mature S. aureus Newman biofilms were grown in a model of a soft tissue wound, then treated with 
either sterile water (control) or eyesalve (n = 3–5 replicates per treatment) for 24 h before recovering bacteria for 
CFU counts. All batches showed killing, and the log drop in treated vs control wounds was calculated. Raw data 
are provided in the Data Supplement.
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experimental error, two MIC test (ESO batches 28, 29) were lost; we did not repeat this due to the time delay 
between the initial and repeated test potentially affecting concentrations of compounds present, and thus activity.
All of these 12 batches eradicated mature S. aureus Newman biofilms in the synthetic wound assay (see Data 
Supplement). The results of biofilm killing assays for five representative batches are depicted in Fig. 6A, alongside 
a biofilm killing assay conducted for preparations of 100, 300 or 500 μg·ml−1 of purified allicin. Purified allicin at 
concentrations similar to those found in ESO, had much less anti-biofilm activity (Fig. 6B), and garlic prepara-
tions with the same allicin concentration as ESO had no activity (data supplied in the supplementary data file). 
Therefore, allicin alone does not explain either the activity of ESO against biofilm-grown bacteria or its activity 
against planktonic cultures.
Figure 3.  Bald’s eyesalve (ESO) activity against eight example strains of bacteria that commonly cause chronic 
wound infections. Planktonic cultures were grown for 6 h in synthetic wound fluid. Cultures were treated with 
ESO (batches 16–18) or sterile water (CT) to a final concentration of 33% v/v (n = 3–5 replicates per treatment). 
After 18 h bacteria were recovered for CFU counts. The dashed line represents the limit of detection by plating. 
For S. maltophila and S. aureus USA300, where we did not observe complete killing, we used ANOVA to 
determine that the CFU recovered from ESO-treated wounds was significantly different from control wounds (S. 
aureus USA300:  F2,14 = 3,458, p < 0.001; S. maltophilia:  F3,8 = 87.41, p < 0.001). Data were log transformed to meet 
the assumptions of linear modelling. A Dunnett’s test was conducted to compare the CFU of the three batches 
with the CFU of the controls. All 3 batches of ESO were significantly different from their respective controls for 
both isolates (all p < 0.001). Raw data and R scripts are supplied in the Data Supplement.
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Figure 4.  Bald’s eyesalve (ESO) anti-biofilm activity. Mature biofilms of various isolates were grown in a 
model of a soft tissue wound, then treated with either sterile water (control, CT) or eyesalve (batches 16–18), 
to a final concentration of 33% (v/v), for 24 h before recovering bacteria for CFU counts (n = 3–5 replicates 
per treatment). The dashed line represents the limit of detection by plating. For S. aureus Newman, S. aureus 
USA300, and S. epidermidis, where we did not observe complete killing, we used ANOVA to determine that the 
CFU recovered from ESO-treated wounds was significantly different from control wounds (S. aureus Newman: 
 F3,8 = 107, p < 0.001; S. aureus USA300:  F3,14 = 103.5, p < 0.001; S. epidermidis:  F3,14 = 63.86, p < 0.001). Data were 
log transformed to meet the assumptions of linear modelling. A Dunnett’s test was conducted to compare the 
CFU of the three batches with the CFU of the controls. All 3 batches of ESO were significantly different from 
their respective controls for all three isolates (all p < 0.001). Raw data and R scripts are supplied in the Data 
Supplement.
Table 1.  Minimum inhibitory concentration (MIC) of ESO or individual ingredients. MICs were tested in 
both Mueller–Hinton Broth (MHB) or synthetic wound fluid (SWF). MICs are presented as modal values of 3 











MHB SWF MHB SWF MHB SWF MHB SWF
ESO 1.56 6.25 3.13 3.13 1.56 3.13 25 25
Onion  > 50  > 50  > 50  > 50  > 50  > 50  > 50  > 50
Garlic 1.56 12.5 3.13 3.13 1.56 6.25 33 33
Wine  > 50  > 50  > 50  > 50  > 50  > 50  > 50  > 50
Bile  > 50  > 50  > 50  > 50  > 50  > 50  > 50  > 50
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Discussion
The activity of a range of natural products against microbes in simple in vitro assays (agar diffusion, broth 
microdilution or simple surface-attached biofilm assays) demonstrates their potential as a source of novel 
 antibiotics29–31. However, the standard approach of purifying individual compounds from natural products rarely 
produces clinically useful products, and potent activity against planktonic bacteria in standard lab media rarely 
translates to in vivo efficacy. This is an especially pressing problem in the case of biofilm infections. Biofilms are 
much harder to treat due to reduced penetration of antibiotics through the extracellular matrix and the enhanced 
tolerance of biofilm-grown cells to many in-use  antibiotics6,11. Biofilm infections of wounds (e.g. burns, diabetic 
foot ulcers), medical implants (e.g. artificial joints, catheters), the lungs (e.g. in cystic fibrosis) and other body 
sites impose a major health and economic  burden32 and can be effectively untreatable. Non-healing, infected foot 
ulcers, which can be a complication of diabetes, provide an especially sobering example. Even if the infection is 
apparently successfully treated, there is a high chance of recurrence and an estimated 50% of those affected die 
within 5 years of ulcer development. Management of diabetic foot ulcers costs the UK’s NHS £650 M per  year33.
Historical medical manuscripts often prescribe complex preparations of several ingredients to treat infections. 
Thus, when considering natural products as a potential source of anti-biofilm agents, we must consider the pos-
sibility that any efficacy they may possess could rely on creating a cocktail of different products. Understanding 
the relationship between combinations of natural products and antimicrobial activity may generate a novel way 
to create new antibiotics from botanicals. Here, we confirm Bald’s eyesalve as an example of an “ancientbiotic” 
that requires the combination of all ingredients for potent activity against a panel of clinically important bacte-
rial strains.
Our research builds on previous  work19–21 to show that Bald’s eyesalve can eradicate planktonic cultures of 
a range of problematic Gram-positive and Gram-negative bacteria including P. aeruginosa, A. baumannii, E. 
cloacae, S. maltophilia, S. aureus, S. epidermidis and S. pyogenes. It is also able to cause a 4-log reduction in viable 
cell counts in planktonic cultures of the especially problematic MRSA. Despite the widely understood problems 
of treating  biofilms6,11, Bald’s eyesalve was also able to significantly reduce viable cell counts in biofilms of S. 
epidermidis and MRSA and was able to completely eradicate biofilms of S. aureus Newman, A. baumannii and S. 
pyogenes, in an established soft-tissue wound  model24. However, although there was promising planktonic activ-
ity against P. aeruginosa, E. cloacae and S. maltophilia, variable or no activity was seen against biofilm cultures 
of these isolates in the wound model. This highlights the importance of investigating the anti-biofilm activity of 
candidate antibacterial agents, rather than extrapolating from the results of planktonic assays. Bald’s eyesalve 
shows great promise as an effective antimicrobial candidate, although further development and combination 
with biofilm-degrading adjuvants may be necessary to achieve activity against species such as P. aeruginosa. It 
would also be worthwhile to investigate potential anti-virulence effects of Bald’s eyesalve; given garlic’s ability 
to interfere with quorum  sensing34,35 it is possible Bald’s eyesalve may usefully modulate bacterial behaviour 
when it does not  kill36,37.
Each of Bald’s eyesalve ingredients has known antimicrobial properties or compounds (onion and  garlic28,31,38, 
 bile39–41,  wine42–44). We explored the contribution of all four ingredients to both planktonic and biofilm activity 
of Bald’s eyesalve to build a picture of their relative contributions. Planktonic activity appeared almost entirely 
attributable to garlic. However, tests against S. aureus Newman biofilms, grown in a synthetic wound model, 
showed garlic exhibited no antibacterial activity in this more clinically-relevant setting. In fact, no preparation 
which omitted any one ingredient possessed full activity in the biofilm assay. This confirms our previously 
published finding that Bald’s eyesalve anti-biofilm activity is contingent on the presence of all four  ingredients19.
Our results against planktonic cultures of S. aureus and P. aeruginosa align with a report by Fuchs et al. 2018, 
that garlic alone, and specifically allicin, accounts for the majority of the planktonic activity of Bald’s remedy. 
Allicin is a defensive compound that is converted from alliin by the enzyme alliinase, upon damage to the plant 
tissue. Allicin can kill a wide range of both Gram-negative and Gram-positive bacteria in vitro26 due to the 
thiosulfinate group (–S(O)–S–) reacting with many cellular proteins in the  pathogen45. We therefore explored 
the role of allicin in Bald’s eyesalve in detail.
Crucially, we found that 12 batches of Bald’s eyesalve were able to elicit much greater anti-biofilm activity than 
purified allicin at comparable concentrations. Pure allicin at a concentration of 500 μg·ml−1 was able to reduce 
viable cell numbers by 2–3 logs, whereas Bald’s eyesalve batches containing 275–486 μg·ml−1 allicin were able 
Table 2.  Minimum inhibitory concentration (MIC) of ESO or preparations omitting a single ingredient. MICs 
were tested in both Mueller–Hinton Broth (MHB) and synthetic wound fluid (SWF). MICs are presented as 
modal values of 3 different batches (ESO 22–24; with 3 replicate MIC tests per batch) and are the percentage of 










MHB SWF MHB SWF MHB SWF MHB SWF
ESO  < 0.78 12.5 3.13 12.5 1.56 6.25 25 25
Omitting
Onion  < 0.78 12.5 3.13 12.5 3.13 6.25 25 25
Garlic 50 50 50 50 50  > 50  > 50  > 50
Wine  < 0.78 6.25 3.13 12.5 1.56 6.25 25 50
Bile  < 0.78 6.25 3.13 12.5 1.56 6.25 25 50
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to cause a 6–7 log drop and eradicate the biofilms. Even in planktonic tests, we found that the concentration of 
allicin in the MIC of these batches of Bald’s eyesalve was lower than the MIC of purified allicin. Together, these 
results clearly illustrate that in addition to allicin, other ingredients in Bald’s eyesalve contribute to its activity. 
This highlights the importance of the combination of ingredients.
The differences between our findings and those of Fuchs et al. are partly explained by the contrasts between 
bacterial tolerance to killing (i) in MHB versus synthetic wound fluid; and (ii) in planktonic culture versus estab-
lished biofilms. This highlights the differences in antibiotic susceptibility often seen in host-mimicking media 
versus standard  MHB17,18,46. Further, the allicin concentrations found in our batches of Bald’s eyesalve were lower 
than that found in Fuchs et al. The highest allicin concentration we measured was 486 μg·ml−1, compared with 
Fuchs et al.’s 836 μg·ml−1.
We think it unlikely that this is due to the differences in quantification methods used as both are appropriate. 
We used HPLC, a method that has been widely used  previously27,47–50 and is accepted to produce consistent and 
accurate results. Previous papers using HPLC have detected allicin concentrations ranging from 1 μg·ml−1 to 
2 mg·ml−1 27,49, a range that the results in this paper lie within. Fuchs et al. 2018 used quantitative NMR (qNMR), 
Figure 5.  Contribution of ingredients to Bald’s eyesalve (ESO) anti-biofilm activity. Mature biofilms of S. 
aureus Newman, grown in a soft tissue wound model, were treated with water (CT) or treatment for 24 h, 
before recovering bacteria for CFU counts. Dashed lines represent the detection limit by plating. (A) ESO 
and individual ingredients, with the concentrations of each ingredient in the whole remedy and individual 
preparation being equal. Three batches of preparations are shown, ESO 19 (white), 20 (grey) and 21 (black); 
(n = 3 replica biofilms per treatment). Data was square-root transformed to meet assumptions of linear 
modelling. ANOVA showed significant differences between treatments  (F4,30 = 389.215, p < 0.001), but not 
between batches  (F2,30 = 1.24, p = 0.305) and the effect of treatment did not depend on the batch (interaction 
 F8,30 = 0.930, p = 0.507). To compare each treatment to the untreated controls, we used a new ANOVA to fit least-
squares means and variances for CFU recovered for each treatment (excluding controls), averaged over the three 
batches. Fitted means were compared with untreated controls using unpaired Welch’s t-tests. ESO treatment 
caused a significant decrease in CFU (t2.93 = 9.18, p = 0.003). Garlic, onion and wine caused small but significant 
increases (t2.93 = 9.05, p = 0.003, t2.93 = 9.61, p = 0.003, t2.93 = 11.1, p = 0.002), bile had no significant effect 
(t2.93 = 2.44, p = 0.094). (B) ESO and batches with one ingredient omitted and replaced with water. Three batches 
of preparations are shown, ESO 22 (white), 23 (grey) and 24 (black) (n = 3 replica biofilms per treatment). 
Data was log-transformed to meet the assumptions of linear modelling. ANOVA showed an effect of treatment 
 (F4,26 = 162, p < 0.001) but not batch  (F2,26 = 18.7, p < 0.001). The effect of treatment depended on the batch 
(interaction  F8,26 = 5.85, p < 0.001), however, the rank order of treatments from least to most active were the same 
for each batch. As only two control data points were obtained, one-sample t-tests were performed to compare 
least-squares mean CFU in the treated wounds to the mean CFU in control wounds. A significant decrease in 
CFU was found for ESO and all dropouts (p ≤ 0.002) except the wine dropout (p = 0.202). Dunnett’s test revealed 
all dropouts were less active than the full ESO (all p < 0.001). Raw data and full statistical results are supplied in 
the Data Supplement.
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which too has advantages and is being increasingly used in quantification of  concentrations51. It is more likely 
that our Bald’s eyesalve preparations really do have different allicin concentrations. Alliin is released from storage 
vesicles and converted to allicin upon damage to tissue: Fuchs et al., 2018 used a food processor, in comparison 
to our pestle and mortar, which may have resulted in greater damage to the tissue and therefore greater release 
of alliin and more allicin created. Further, different garlic varieties are thought to have different activities and 
 compositions52–56 and our research labs are based in different continents, which presumably results in differ-
ent garlic varieties and growth conditions. The higher allicin concentration may explain the slightly increased 
planktonic activity seen in Fuchs et al. This may also be due to their use of agitation in MIC assays, as agitation 
is known to lower the  MIC57.
Figure 6.  Antimicrobial activity of Bald’s eyesalve (ESO) and allicin standards. Mature S. aureus Newman 
biofilms were grown in a model of a soft tissue wound, then treated with either water (CT) or treatment for 
24 h, before recovering bacteria for CFU counts. (A) Biofilms treated with 5 ESO batches, with their respective 
allicin concentrations indicated. (B) External allicin standards diluted in water. The dashed line represents 
the limit of detection by plating. To statistically analyse, data were log transformed to meet the assumptions 
of linear modelling. A one-way ANOVA was performed and found a significant difference between allicin 
treatments and control cells  (F3,9 = 141, p < 0.001). A Dunnett’s test was conducted to compare the CFU of the 
three allicin concentrations with the CFU of the controls. Of the concentrations, 300 μg·ml−1 and 500 μg·ml−1 
were significantly different (p < 0.001), 100 μg·ml−1 was not significantly different (p = 0.247). Raw data and full 
statistical results are supplied in the Data Supplement.
Table 3.  Minimum inhibitory concentrations (MIC) were calculated for fresh Bald’s eyesalve (n = 12; batches 
19–30), garlic only preparations (n = 3) and external allicin standards (n = 3). Allicin concentrations for each 
batch were quantified using HPLC and calculated using an allicin calibration curve. MICs were measured 
in synthetic wound fluid. The allicin concentration in the MIC of each batch, and the allicin concentration 
present in the biofilm treatment experiments, is calculated and the results of biofilm treatment experiments are 
provided for reference. Raw data is supplied in the Data Supplement.
Treatment
Allicin concentration range 
(mean ± s.e.) Allicin concentration in MIC
Biofilm activity (log drop from 
control)
Average predicted allicin 
concentration in biofilm treatment
ESO 275—486 (391 ± 19) μg·ml-1 11—39 μg·ml-1 Eradicated biofilm (> 5) 142 μg·ml-1
Garlic only 358—434 (389 ± 19) μg·ml-1 45—54 μg·ml-1 No activity (0) 160 μg·ml-1
Allicin Standard 62.5 μg·ml-1 Partial activity (2.6) 167 μg·ml-1
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The step in the early Medieval remedy which specifies that the onion and garlic be ground together would 
have been conducted manually—most likely with a pestle and mortar. We have found that this process gener-
ates sub-bactericidal concentrations of allicin, which is complemented or synergised by the presence of other 
ingredients to form a biofilm-killing preparation. This demonstrates how contingent explorations of natural 
product antimicrobials are on material preparation and testing conditions. This result is also interesting because 
allicin can be toxic in high  concentrations58. Reducing the amount of allicin present but maintaining full activity 
against bacterial biofilms may be key to producing a safe topical treatment. Further work is needed to elucidate 
the exact combination of natural products responsible for the anti-biofilm activity.
Contrary to many papers in the  literature42,59,60, we found that wine possessed very limited planktonic anti-
microbial activity, and could not kill S. aureus in biofilms. Despite this, its absence from the full remedy causes 
a large drop in activity against S. aureus biofilms. Taken together, these observations suggest that the role of 
wine in the full recipe may be more to do with its physical properties, perhaps its ethanol content and/or low 
pH. Ethanol is a well-known extraction solvent and may allow better extraction of compounds from the plant 
 matter61, or allow better diffusion through biofilms, while the lower pH may activate pH-dependent compounds. 
The answer may lie in the combination of these properties, as the activity of wine reported in the literature cannot 
be attributed exclusively to one aspect of it: the physicochemical environment plays a large role in the activity of 
 wine62. Although pH and ethanol concentrations corresponding to those found in various wines have minimal 
effects on pathogens, without them the compounds within the wine have reduced  activity62.
Similarly, individual preparations of onion and bile, prepared as they would be for Bald’s eyesalve, possessed 
no planktonic antibacterial activity. This is contrary to the literature that has shown these ingredients to have 
activity against various  strains39,63. The most likely cause for this disparity is the difference in the preparation or 
the dilution effect when combined with other ingredients. However, the removal of onion or bile significantly 
reduced the anti-biofilm activity against S. aureus, indicating the importance of their presence within the whole 
remedy. They may be providing additional compounds necessary for the full killing effect in biofilms or aiding 
penetration/activity of antibacterial compounds from other ingredients.
Here, we have shown for the first time that Bald’s eyesalve has anti-biofilm activity against several clinically 
relevant bacteria, and we confirm our earlier work which concluded that this activity is dependent on combining 
all the ingredients. Interestingly, statistical analysis of the surviving portion of Bald’s Leechbook (London, British 
Library, Royal MS 12 D XVII) showed that garlic is combined with a second Allium species significantly more 
often than would be expected given the frequency of use of either garlic or other Allium species across the book 
if ingredients were combined  randomly64. Perhaps the patterns of ingredient combinations used by pre-modern 
physicians do, in at least some cases, reflect a requirement for combinatorial activity of several natural products 
to produce an efficacious antimicrobial preparation.
Research into natural products is often focussed on isolating single compounds, however, here we provide 
evidence that in doing so potent anti-biofilm mixtures can be overlooked. Viewing natural products in this 
way has the potential to open a vast new source of antimicrobials that can overcome the inherent difficulties 
of treating biofilm infections. In a companion  manuscript21, we describe the low potential of Bald’s eyesalve 
for producing irritation or impeding wound healing. Future work will determine whether our results translate 
into a candidate natural product cocktail for incorporation into wound ointments or dressings. At present, we 
conclude by re-stating the exciting potential for pre-modern European medical texts to contain antibacterial 
preparations of clinical interest.
Table 4.  Bacterial strains used in the study.
Species Strain Notes
Gram-positive
Staphylococcus aureus Newman Standard laboratory strain, used in initial activity testing of all fresh eyesalve batches
Staphylococcus aureus USA300 Los Angeles County clone Well-studied example of community-acquired MRSA
Staphylococcus aureus 6 human carriage isolates 1 MRSA + 5 MSSA, gifted by Ruth Massey
Staphylococcus aureus 6 clones isolated from a chronic post-surgical wound MSSA, with thanks to Tim Sloan
Staphylococcus epidermidis 1,457 Standard laboratory strain, with thanks to Kim Hardie
Streptococcus pyogenes Clinical isolate Nottingham University Hospitals biobank, strain ref. 15W905066
Gram-negative
Acinetobacter baumannii Clinical isolate Nottingham University Hospitals biobank, strain ref. 12W125768
Enterobacter cloacae Clinical isolate Nottingham University Hospitals biobank, training isolate
Escherichia coli K12 Standard laboratory strain
Pseudomonas aeruginosa PA14 Standard laboratory strain
Stenotrophomonas maltophilia Clinical isolate Nottingham University Hospitals biobank, training isolate
11
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:12687  | https://doi.org/10.1038/s41598-020-69273-8
www.nature.com/scientificreports/
Materials and methods
Bacterial strains and culture conditions. Strains used are listed in Table 4. All cultures were grown 
aerobically at 37 °C and Miller’s LB agar (Melford) was used for plating.
Media. Synthetic wound fluid (SWF) comprised equal volumes of foetal bovine serum (Gibco) and peptone 
water (Sigma-Aldrich)24. Mueller–Hinton Broth (MHB) was obtained from VWR. HyClone water (GE Health-
care) was used throughout.
Bald’s eyesalve reconstruction. Bald’s eyesalve was prepared as previously  reported19. Garlic and onions 
were purchased from supermarkets or greengrocers. As lab work continued throughout all seasons of the year, 
and was conducted in two locations (Warwick and Nottingham), it is possible that different varieties of garlic 
and onion, or the same variety grown in different locations, were used in different batches of the eyesalve. The 
outer skin of the garlic and onion (sourced from local greengrocers) was removed. The garlic and onion were 
finely chopped, and equal volumes of garlic and onion were crushed together using a mortar and pestle for 
2 min. Various sized batches of Bald’s eyesalve were used throughout this paper, ranging from final volumes of 
30 ml–400 ml, the average weight used was 14.1 ± 1.5 g of onion and 15.0 ± 1.3 g of garlic per 100 ml of Bald’s 
eyesalve.
The crushed onion and garlic were then combined with equal volumes of wine (Pennard’s organic dry white, 
11% ABV, sourced from Avalon Vineyard, Shepton Mallet) and bovine bile salts (Sigma Aldrich) made up to 
89 mg·ml−1 in water and sterilised by exposing to UV radiation for 10 min (Carlton Germicidal Cabinet fitted 
with a 2537 Å, 8-W UV tube). The mixture was stored in sterilised glass bottles in the dark at 4 °C for 9 days, 
after which it was strained and centrifuged for 5 min at 1,811 g. The supernatant was then filtered using What-
man 1,001–110 Grade 1 Qualitative Filter Paper, Diameter: 11 cm, Pore Size: 11 μm. Filtered Bald’s eyesalve was 
stored in sterilised glass vials in the dark at 4 °C.
For ease of reading, batches are numbered as they appear within the paper. The key for their batch name is 
provided in the Data Supplement.
Preparation of individual ingredients and dropouts. Individual ingredients were prepared such that 
their concentrations were equal to concentrations present in the full remedy, a schematic is provided in Fig. S1. 
To achieve comparable concentrations, each ingredient was prepared as it would be for the full remedy (onion 
and garlic crushed separately from each other), with all other ingredients substituted with the same volume of 
water. A similar process was followed for “dropout” batches, where one ingredient at a time was systematically 
excluded from the remedy and replaced with an equal volume of water to maintain comparable concentrations 
to the original remedy.
Planktonic killing assay. Bacteria were cultured aerobically at 37 °C on LB agar for 18–24 h. Several colo-
nies were then inoculated into 5 ml SWF and incubated for 6 h at 37 °C on an orbital shaker. Aliquots of each 
bacterial culture (100 μl) were added to wells of Corning Costar TC-Treated 96-Well Plate and 50 μL of the 
eyesalve batch to be tested was added to 5 wells per strain. 50 μL of water was used as a negative control. Plates 
were incubated in Tecan SPARK 10 M at 37 °C for 18 h with periodic orbital shaking (10 s at 20 min intervals). 
Serial dilutions were then performed and plated on LB agar plates.
Minimum inhibitory concentration assay by broth microdilution. The minimum inhibitory con-
centrations (MIC) of eyesalve, single ingredients, dropout batches and allicin were determined as described by 
Wiegand, Hilpert and Hancock (2008) in MHB and in SWF. Treatments, or water as a negative control, were 
serially diluted with media in Corning Costar TC-Treated 96-Well Plates, following the scheme in Table 5. Bac-
terial isolates were streaked onto LB agar to obtain single colonies. After 18–24 h incubation at 37 °C, three to 
five morphologically similar colonies were transferred to phosphate-buffered saline (PBS) and diluted to 0.5 
McFarland standard  (OD600 0.08–0.1). This suspension was diluted 1 in 100 in media. The bacterial suspension 
was then added to the treatment dilutions, resulting in another twofold dilution and 5 × 105 CFU/ml. The high-
est final concentration of eyesalve, single ingredient or dropout batch tested was 50%. Plates were incubated for 
Table 5.  Final volumes and calculated percentages of Bald’s eyesalve in wells of 96-well plates used for MIC.
Well Bald’s eyesalve (μl) Media (μl) Bacterial suspension (μl) Final volume (μl) % ESO in well
A 50 0 50 100 50
B 33 17 50 100 33
C 25 25 50 100 25
D 12.5 37.5 50 100 12.5
E 6.25 43.75 50 100 6.25
F 3.13 46.87 50 100 3.13
G 1.56 48.44 50 100 1.56
H 0.78 49.22 50 100 0.78
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18 h at 37 °C. Results were visually checked for turbidity, and MIC values are the lowest concentration where 
growth was not visible.
Biofilm killing assay in synthetic wounds. Biofilms were created in a synthetic soft-tissue wound 
model as described by Werthén et al. (2010; 24) and as used in our previous work 19. Briefly, synthetic wounds 
were created on ice and comprised 2 mg·ml−1 collagen, 0.01% acetic acid, 60% [vol/vol] SWF, 10 mM sodium 
hydroxide. Synthetic wounds were incubated at 37 °C for 1 h to allow collagen to polymerise and placed under 
UV light for 10 min to ensure no contamination. Wounds were either 400 μl in 24-well culture plates or 200 μl 
in 48-well plates.
Bacteria were incubated aerobically in SWF on an orbital shaker for 6 h at 37 °C, after which cultures were 
diluted to  OD600 of 0.1–0.2 with fresh SWF. Bacteria suspension was added to each synthetic wound (100 μl in 
400 μl wounds or 50 μl in 200 μl wounds) and incubated at 37 °C for 24 h to allow biofilm formation.
Wounds containing mature biofilms were then exposed to Bald’s eyesalve or water (200 μl in 400 μl wounds 
or 100 μl in 200 μl wounds). Bacteria were recovered by treating with 600 μl (400 μl wounds) or 300 μl (200 μl 
wounds) of 0.5 mg·ml−1 collagenase type 1 (EMD Millipore Corp, USA) for 1 h at 37 °C to break down the matrix; 
the resulting liquid was serially diluted and plated on LB plates. Plates were incubated at 37 °C overnight, colonies 
were counted, and CFU/wound calculated.
High‑performance liquid chromatography quantification of allicin. Allicin is an unstable and 
reactive compound under gas chromatography  settings65, therefore, high-performance liquid chromatography 
(HPLC) was used to determine allicin  concentrations65.
Various preparations of Bald’s eyesalve were analysed by reversed-phase HPLC on an Agilent 1,200 series 
system fitted with an Agilent ZORBAX Eclipse XDB-C18, 150 × 4.6 mm, 5 μm particle size column and diode 
array detection at 210 nm. A gradient of methanol (5–95%) in water was used at a flow rate of 1 ml·min−1 over 
30 min. Injection volume was 10 μl, and the column temperature was 25 °C.
To identify the concentration of allicin in eyesalve preparations, a calibration curve was prepared by seri-
ally diluting an external allicin standard (Abcam, Cambridge) in water (twofold dilutions, from 750 μg·ml−1 to 
0.5 μg·ml−1). External standards were run through HPLC as described above (n = 2) and allicin peak area, in the 
210 nm reading, was plotted against concentration (μg·ml−1) (Fig. S2 and Data Supplement). Allicin external 
standards had a retention time of approximately 15 min (Fig. S2). This peak was confirmed in Bald’s eyesalve by 
comparing fresh eyesalve to the same batch spiked with additional allicin standard. The suspected peak increased 
as expected (Fig. S2).
Statistics. Data were analysed in R v3.5.1 (R Core Team, 2018) using the car66, lsmeans67, multcomp68 and 
FSA69 packages. Raw data and R code for all experiments are provided in the Data Supplement. Graphs were 
produced with DataGraph 4.5.1 (Visual Data Tools Inc. 2006–2020).
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